Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat)

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Spolding, Briana ^a   Connor, Timothy ^a   Wittmer, Carrie ^b   Abreu, Lelia L F ^a   Kaspi, Antony ^c   Ziemann, Mark ^c   Kaur, Gunveen ^d   Cooper, Adrian ^a   Morrison, Shona ^a   Lee, Scott ^a   Sinclair, Andrew ^a   Gibert, Yann ^a   Trevaskis, James L ^b   Roth, Jonathon D ^b   El Osta, Assam ^c   Standish, Richard ^a   Walder, Ken ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CHOLESTEROL INTAKE; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIET SUPPLEMENTATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATOMEGALY; HISTOPATHOLOGY; INFLAMMATION; LIPID METABOLISM; LIVER CELL; LIVER FIBROSIS; LIVER METABOLISM; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PSAMMOMYS OBESUS; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION PROFILING; GERBILLINAE; LIPID METABOLISM; LIVER; MALE; MICE;

EID: 84908544295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092656     Document Type: Article

References (32)

1. Masterton GS, Plevris JN, Hayes PC (2010) Omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 31: 679-92.
2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, et al. (2011) Prevalence of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-31.
3. Obika M, Noguchi H (2012) Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 145754. doi: 10.1155/2012/145754.
4. Brunt EM (2010) Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 195-203.
5. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-21. (Pubitemid 40770284)
6. Moseley RH (2008) Therapy for nonalcoholic fatty liver disease. J Clin Gastroenterol 42: 332-5.
7. Hebbard L, George J (2011) Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 8: 35-44.
8. Takahashi Y, Soejima Y, Fukusoto T (2012) Animal models of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. W Journal Gastroenterology 18: 2300-2308.
9. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest; 118: 829-38. (Pubitemid 351364588)
10. Barnett M, Collier GR, Collier FM, Zimmet P, O'Dea K (1994) A cross-sectional and shortterm longitudinal characterisation of NIDDM in Psammomys obesus. Diabetologia 37: 671-6. (Pubitemid 24210222)
11. Walder KR, Fahey RP, Morton GJ, Zimmet PZ, Collier GR (2000) Characterization of obesity phenotypes in Psammomys obesus (Israeli sand rats). Int J Exp Diabetes Res 1: 177-84.
12. Walder K, Oakes N, Fahey RP, Cooney G, Zimmet PZ, et al. (2002) Profile of dyslipidemia in Psammomys obesus, an animal model of the metabolic syndrome. Endocr Regul 36: 1-8.
13. Collier GR, McMillan JS, Windmill K, Walder K, Tenne-Brown J, et al. (2000) Beacon: a novel gene involved in the regulation of energy balance. Diabetes; 49: 1766-71.
14. Walder K, Kantham L, McMillan JS, Trevaskis J, Kerr L, et al. (2002) Tanis: a link between type 2 diabetes and inflammation? Diabetes 51: 1859-66. (Pubitemid 34564299)
15. Maislos M, Medvedovskv V, Sztarkier I, Yaari A, Sikuler E (2006) Psammomys obesus (sand rat), a new animal model of non-alcoholic fatty liver disease. Diabetes Research and Clinical Practice 72: 1-5.
16. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
17. Sinclair AJ, O'Dea K, Dunstan G, Ireland PD, Niall M (1987) Effects on plasma lipids and fatty acid composition of very low fat diets enriched with fish or kangaroo meat. Lipids 22: 523-9.
18. Kleiner DE, Brunt EM (2012) Nonalcoholic fatty liver disease: Pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32: 3-13.
19. Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL (2003) Novel putative SREBP and LXR target genes identified by microanalysis in liver of cholesterol-fed mice. J Lipid Research 44: 2109-2119. (Pubitemid 37509626)
20. Boone LR, Brooks PA, Niesen MI, Ness GC (2011) Mechanism of resistance to dietary cholesterol. J Lipidsdoi:10.1155/2011/101242.
21. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, et al. (2012) Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302: G762-G772.
22. Savard C, Tartaglione EV, Kuver R, Geoffrey Haigh W, Farrell GC, et al. (2012) Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology doi: 10.1002/hep.25789.
23. Du R, Xue J, Wang HB, Zhang Y, Xie ML (2011) Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression. Eur J Pharmacol 666: 183-8.
24. Rudel L, Deckelman C, Wilson M, Scobey M, Anderson R (1994) Dietary cholesterol and downregulation of cholesterol 7 alpha-hydroxylase and cholesterol absorption in African green monkeys. J Clin Invest 93: 2463-72. (Pubitemid 24177160)
25. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, et al. (2009) Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 49: 1375-84.
26. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, et al. (2006) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26: 613-20.
27. Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, et al. (2009) Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res 39: 366-73.
28. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, et al. (2007) Reevaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20: 351-8.
29. Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballeria J, et al. (2009) Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 50: 789-96.
30. Chang X, Yan H, Fei J, Jiang M, Zhu H, et al. (2010) Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 51: 2504-15.
31. Zhang B, Xue C, Hu X, Xu J, Li Z, et al. (2012) Dietary sea cucumber cerebroside alleviates orotic acid-induced excess hepatic adipopexis in rats. Lipids Health Dis 11: 48. doi: 10.1186/1476-511X-11-48.
32. Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, et al. (2005) Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 16: 631-5.